TCI Wealth Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

TCI Wealth Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-991	Closed	-$4K	–	2352
2021 Q4	$4K	Buy	+991	New	+$4.81K	﹤0.01%	1848

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCI Wealth Advisors's LXRX Position: Q1 2022 in Review

TCI Wealth Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2022, closing a stake of 991 shares — an estimated $4K sold.

TCI Wealth Advisors first reported a position in LXRX in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 101 funds tracked by Wall St. Rank hold LXRX as of Q1 2022.

TCI Wealth Advisors reported no remaining Lexicon Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
TCI Wealth Advisors sold 991 Lexicon Pharmaceuticals shares in Q1 2022, an estimated $4K.
TCI Wealth Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2021 and held it in 1 quarter.
TCI Wealth Advisors's Lexicon Pharmaceuticals position peaked at $4K in Q4 2021.
101 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2022.

Based on TCI Wealth Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.